Compare Dyne Therapeutics Inc. Common Stock (DYN) vs HP Inc (HPQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs HP Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.07 (market cap $2.86B), while HP Inc trades at $30.43 (market cap $27.62B). The key difference: HP Inc is far larger — about 9.7× Dyne Therapeutics Inc. Common Stock's market cap, and HP Inc pays a 3.92% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and HP Inc for 70 Days on average.
| DYN | HPQ | |
|---|---|---|
Market Cap | $2.86B | $27.62B |
Volume | 3,341,579 | 12,820,066 |
Sector | Health | Technology |
52-Week High | $26.78 | $35.48 |
52-Week Low | $14.60 | $18.20 |
Typical Hold Time | 0 Days | 70 Days |
Enterprise Value | $2.18B | $33.79B |
Dividend Yield | — | 3.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
HPQ trades at $30.46, up 1.98% today, with a bearish technical signal despite recent earnings beats. The company maintains stable cash flow generation ($460M net in 2025) and pays a $0.30 dividend, but faces PC market headwinds with 2027 industry volume declines projected. Valuation appears reasonable with P/E of 11.69 and P/S of 0.48, though negative shareholder equity raises concerns.
The outlook is mixed: attractive valuation and dividend yield support the stock, but PC market challenges and negative equity position create significant risks. Analyst consensus is cautious with a $25.75 price target below current levels, suggesting limited near-term upside potential amid industry uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →
